India, July 1 -- As N-FIS adoption grows across clinical practice, how do you see the company's growth trajectory evolving through March 2027?

We are in a strong growth phase right now, with revenues increasing as more doctors start using N-FIS in their everyday practice. A big part of this is our doctor-led model and growing on-ground presence; we have already administered N-FIS to over 1 lakh patients across 25 states and 200+ cities in India. As adoption builds, especially in areas like paediatric vaccination, we're also expanding into IVF, growth hormones, GLP-1, pulmonology, and general practice.

Our collaboration with Intas Pharmaceuticals in the IVF segment is another important step, helping us reach more clinics and scale usage ...